. 2017 Apr 13;25(7):1467–1475. doi: 10.1016/j.ymthe.2017.03.013

Table 1.

LNP siRNA Drugs in Clinical Trials^a

Name	LNP-Encapsulated siRNA	Indication	Status	Company
Patisiran	siRNA versus transthyretin	transthyretin-induced amyloidosis	phase III	Alnylam
ARB 1467	siRNAs versus 3 HBV proteins	hepatitis b	phase II	Arbutus
	siRNA versus PLK1	hepatocellular carcinoma	phase I/II	Arbutus
	siRNA versus KSP and VEGF	liver cancer	phase I	Alnylam
	siRNA versus PCSK9	atherosclerosis	phase I	Alnylam

LNP, lipid nanoparticle; siRNA, small interfering RNA.

As of 2017.